193 related articles for article (PubMed ID: 30312216)
41. Higher administered activities of radioactive iodine are associated with less structural persistent response in older, but not younger, papillary thyroid cancer patients with lateral neck lymph node metastases.
Sabra MM; Grewal RK; Ghossein RA; Tuttle RM
Thyroid; 2014 Jul; 24(7):1088-95. PubMed ID: 24559250
[TBL] [Abstract][Full Text] [Related]
42. Significance of p53-binding protein 1 (53BP1) expression in thyroid papillary microcarcinoma: association with BRAFV600E mutation status.
Mussazhanova Z; Matsuda K; Naruke Y; Mitsutake N; Stanojevic B; Rougounovitch T; Saenko V; Suzuki K; Nishihara E; Hirokawa M; Ito M; Nakashima M
Histopathology; 2013 Nov; 63(5):726-34. PubMed ID: 24004175
[TBL] [Abstract][Full Text] [Related]
43. Papillary thyroid microcarcinoma: an over-treated malignancy?
Wang TS; Goffredo P; Sosa JA; Roman SA
World J Surg; 2014 Sep; 38(9):2297-303. PubMed ID: 24791670
[TBL] [Abstract][Full Text] [Related]
44. Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers.
Dunn LA; Sherman EJ; Baxi SS; Tchekmedyian V; Grewal RK; Larson SM; Pentlow KS; Haque S; Tuttle RM; Sabra MM; Fish S; Boucai L; Walters J; Ghossein RA; Seshan VE; Ni A; Li D; Knauf JA; Pfister DG; Fagin JA; Ho AL
J Clin Endocrinol Metab; 2019 May; 104(5):1417-1428. PubMed ID: 30256977
[TBL] [Abstract][Full Text] [Related]
45. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.
Kim TY; Kim WB; Rhee YS; Song JY; Kim JM; Gong G; Lee S; Kim SY; Kim SC; Hong SJ; Shong YK
Clin Endocrinol (Oxf); 2006 Sep; 65(3):364-8. PubMed ID: 16918957
[TBL] [Abstract][Full Text] [Related]
46. Papillary thyroid carcinoma tall cell variant.
Ghossein R; Livolsi VA
Thyroid; 2008 Nov; 18(11):1179-81. PubMed ID: 18925842
[TBL] [Abstract][Full Text] [Related]
47. Risk-stratified papillary thyroid microcarcinoma: post-operative management and treatment outcome in a single center.
Kanokwongnuwat W; Larbcharoensub N; Sriphrapradang C; Suppasilp C; Thamnirat K; Sakulpisuti C; Kositwattanarerk A; Utamakul C; Sritara C; Chamroonrat W
Endocrine; 2022 Jun; 77(1):134-142. PubMed ID: 35476179
[TBL] [Abstract][Full Text] [Related]
48. A different prognostic value of BRAFV600E mutation positivity in various age groups of patients with papillary thyroid cancer.
Takacsova E; Kralik R; Waczulikova I; Zavodna K; Kausitz J
Neoplasma; 2017; 64(1):156-164. PubMed ID: 27881018
[TBL] [Abstract][Full Text] [Related]
49. Papillary microcarcinoma in comparison with larger papillary thyroid carcinoma in BRAF(V600E) mutation, clinicopathological features, and immunohistochemical findings.
Park YJ; Kim YA; Lee YJ; Kim SH; Park SY; Kim KW; Chung JK; Youn YK; Kim KH; Park DJ; Cho BY
Head Neck; 2010 Jan; 32(1):38-45. PubMed ID: 19475551
[TBL] [Abstract][Full Text] [Related]
50. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
Brose MS; Cabanillas ME; Cohen EE; Wirth LJ; Riehl T; Yue H; Sherman SI; Sherman EJ
Lancet Oncol; 2016 Sep; 17(9):1272-82. PubMed ID: 27460442
[TBL] [Abstract][Full Text] [Related]
51. Positive
Huang S; Qi M; Tian T; Dai H; Tang Y; Huang R
Front Endocrinol (Lausanne); 2022; 13():959089. PubMed ID: 36407316
[TBL] [Abstract][Full Text] [Related]
52. Favorable outcomes of papillary thyroid microcarcinoma concurrent with Graves' disease after radioactive iodine therapy.
Nishihara E; Ito Y; Kudo T; Ito M; Fukata S; Nishikawa M; Akamizu T; Miyauchi A
Endocr J; 2021 Jun; 68(6):649-654. PubMed ID: 33551434
[TBL] [Abstract][Full Text] [Related]
53. Clinical Outcomes of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers.
Toro-Tobon D; Morris JC; Hilger C; Peskey C; Durski JM; Ryder M
Thyroid; 2024 Jan; 34(1):70-81. PubMed ID: 37917101
[No Abstract] [Full Text] [Related]
54. Clinicopathological, immunohistochemical factors and recurrence associated with extrathyroidal extension in papillary thyroid microcarcinoma.
Kim WY; Kim HY; Son GS; Bae JW; Lee JB
J Cancer Res Ther; 2014; 10(1):50-5. PubMed ID: 24762486
[TBL] [Abstract][Full Text] [Related]
55. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma.
Bastos AU; Oler G; Nozima BH; Moysés RA; Cerutti JM
Eur J Endocrinol; 2015 Oct; 173(4):525-40. PubMed ID: 26338373
[TBL] [Abstract][Full Text] [Related]
56. Association of BRAFV600E mutation with ultrasonographic features and clinicopathologic characteristics of papillary thyroid microcarcinoma: A retrospective study of 116 cases.
Chen B; Zhang Z; Wang K; Shang M; Zhao S; Ding W; Du R; Yu Z; Xu X
Clin Hemorheol Microcirc; 2019; 73(4):545-552. PubMed ID: 31306113
[TBL] [Abstract][Full Text] [Related]
57. Does Molecular Genotype Provide Useful Information in the Management of Radioiodine Refractory Thyroid Cancers? Results of a Retrospective Study.
de la Fouchardiere C; Oussaid N; Derbel O; Decaussin-Petrucci M; Fondrevelle ME; Wang Q; Bringuier PP; Bournaud-Salinas C; Peix JL; Lifante JC; Giraudet AL; Lopez J; Borson-Chazot F
Target Oncol; 2016 Feb; 11(1):71-82. PubMed ID: 26285789
[TBL] [Abstract][Full Text] [Related]
58. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.
Xing M; Westra WH; Tufano RP; Cohen Y; Rosenbaum E; Rhoden KJ; Carson KA; Vasko V; Larin A; Tallini G; Tolaney S; Holt EH; Hui P; Umbricht CB; Basaria S; Ewertz M; Tufaro AP; Califano JA; Ringel MD; Zeiger MA; Sidransky D; Ladenson PW
J Clin Endocrinol Metab; 2005 Dec; 90(12):6373-9. PubMed ID: 16174717
[TBL] [Abstract][Full Text] [Related]
59. The Effectiveness of Radioactive Iodine Remnant Ablation for Papillary Thyroid Microcarcinoma: A Systematic Review and Meta-analysis.
Hu G; Zhu W; Yang W; Wang H; Shen L; Zhang H
World J Surg; 2016 Jan; 40(1):100-9. PubMed ID: 26578322
[TBL] [Abstract][Full Text] [Related]
60. Radioactive Iodine Ablation Can Reduce the Structural Recurrence Rate of Intermediate-Risk Papillary Thyroid Microcarcinoma: A Meta-Analysis.
Zhao M; Shi X; Zhang J; Deng S; Zhou Y; Wen R; Lu Y; Zhang B
Comput Math Methods Med; 2022; 2022():8028846. PubMed ID: 36110571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
